1. Aspirin: high number of serious ADR reports

   News item 06 May 2017 Pages: 1 - 1

2. Cobimetinib: risk of haemorrhage and rhabdomyolysis

   News item 06 May 2017 Pages: 2 - 2

3. Idelalisib: indication changes, new warnings in Australia

   News item 06 May 2017 Pages: 3 - 3

4. Japan's PMDA investigation results

   News item 06 May 2017 Pages: 4 - 4

5. Less vascular occlusive events with lower ponatinib dose?

   News item 06 May 2017 Pages: 5 - 5

6. MHRA: potential rebound effect after cessation of Gilenya

   News item 06 May 2017 Pages: 6 - 6

7. New evidence of harm with valproate use in pregnancy

   News item 06 May 2017 Pages: 7 - 7

8. Reports of suicidal behaviour or depression

   News item 06 May 2017 Pages: 8 - 8

9. Review: iodinated contrast medium and hypothyroidism

   News item 06 May 2017 Pages: 9 - 9

10. Revision of labelling related to drug dependence in Japan

    News item 06 May 2017 Pages: 10 - 10

11. US FDA should consider suicide risk with SSRIs in adults

    News item 06 May 2017 Pages: 11 - 11

12. US FDA: warning letters to sellers of illegal cancer treatments

    News item 06 May 2017 Pages: 12 - 12

13. Direct-acting antiviral agents for hepatitis C: HBV reactivation

    Clinical study 06 May 2017 Pages: 13 - 13

14. TNF-α inhibitors: serious bacterial infections in children

    Clinical study 06 May 2017 Pages: 14 - 14

15. Abacavir/dolutegravir/lamivudine

    Case report 06 May 2017 Pages: 15 - 15

16. Abacavir/lamivudine/raltegravir

    Case report 06 May 2017 Pages: 16 - 16

17. Abiraterone

    Case report 06 May 2017 Pages: 17 - 17

18. Abiraterone acetate

    Case report 06 May 2017 Pages: 18 - 18

19. Aciclovir/ivacaftor/lumacaftor interaction

    Case report 06 May 2017 Pages: 19 - 19

20. Adalimumab/mercaptopurine/prednisolone

    Case report 06 May 2017 Pages: 20 - 20

21. Adenosine

    Case report 06 May 2017 Pages: 21 - 21

22. Afatinib

    Case report 06 May 2017 Pages: 22 - 22

23. Alemtuzumab

    Case report 06 May 2017 Pages: 23 - 23

24. Alemtuzumab

    Case report 06 May 2017 Pages: 24 - 24

25. Aminolevulinic-acid/carmustine/temozolomide

    Case report 06 May 2017 Pages: 25 - 25

26. Amoxicillin

    Case report 06 May 2017 Pages: 26 - 26

27. Amphotericin-B

    Case report 06 May 2017 Pages: 27 - 27

28. Amphotericin-B liposomal/cytarabine/voriconazole

    Case report 06 May 2017 Pages: 28 - 28

29. Amrubicin

    Case report 06 May 2017 Pages: 29 - 29

30. Anaesthesia/nitroglycerine

    Case report 06 May 2017 Pages: 30 - 30

31. Antineoplastics

    Case report 06 May 2017 Pages: 31 - 31

32. Antineoplastics

    Case report 06 May 2017 Pages: 32 - 32

33. Antineoplastics

    Case report 06 May 2017 Pages: 33 - 33

34. Antineoplastics

    Case report 06 May 2017 Pages: 34 - 34

35. Antineoplastics

    Case report 06 May 2017 Pages: 35 - 35

36. Antineoplastics

    Case report 06 May 2017 Pages: 36 - 36

37. Antineoplastics

    Case report 06 May 2017 Pages: 37 - 37

38. Antineoplastics/immunosuppressants

    Case report 06 May 2017 Pages: 38 - 38

39. Antiparkinsonians

    Case report 06 May 2017 Pages: 39 - 39

40. Antipsychotics

    Case report 06 May 2017 Pages: 40 - 40

41. Antiretrovirals

    Case report 06 May 2017 Pages: 41 - 41

42. Antiretrovirals

    Case report 06 May 2017 Pages: 42 - 42

43. Antithymocyte globulin/calcineurin-inhibitors/mycophenolate/prednisolone

    Case report 06 May 2017 Pages: 43 - 43

44. Antituberculars

    Case report 06 May 2017 Pages: 44 - 44

45. Antituberculars

    Case report 06 May 2017 Pages: 45 - 45

46. Antivenin-naja/antivenin-bungarus/antivenin-daboia-russelli/antivenin-echis-coloratus

    Case report 06 May 2017 Pages: 46 - 46

47. Apatinib

    Case report 06 May 2017 Pages: 47 - 47

48. Apixaban

    Case report 06 May 2017 Pages: 48 - 48

49. Apixaban

    Case report 06 May 2017 Pages: 49 - 49

50. Aripiprazole

    Case report 06 May 2017 Pages: 50 - 50